Thursday 11 October 2012

Positive Phase 1 trial results for SMT C1100 (Summit PLC) - PPMD Community

Positive Phase 1 trial results for SMT C1100 (Summit PLC) - PPMD Community: Following closely on the heels of the good news about Sarepta’s exon 51 skipping strategy, PPMD is pleased to report that Summit PLC�has been able to achieve sufficient plasma levels of its reformulated utrophin-upregulating drug to justify a phase I/II trial in Duchenne (Read Summit's Press Release). At PPMD we have always believed in “hedging our bets” and investing widely in different therapies, some of which are mutation specific and some of which are not. Unlike exon-skipping strategies, upregulating utrophin is not a mutation specific strategy and, if effective, could potentially benefit anyone with Duchenne

No comments:

Post a Comment